Form S-3ASR Kymera Therapeutics,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall Street rallies, Dow closes at record on Iran talks optimism
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
Kymera Therapeutics (KYMR) PT Raised to $41 at B.Riley
November 1, 2024 5:59 AM EDTB.Riley analyst Kalpit Patel raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $41.00 (from $36.00) while maintaining a Neutral rating.
The analyst comments "Kymera Therapeutics (KYMRNeutral, $41 PT) announced 3Q24 earnings and provided a business update. Patient dosing has commenced for KT-621, the companys STAT6 degrader, with... More
